Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials

JP Neoptolemos; Deborah Stocken; CT Smith; C Bassi; P Ghaneh; E Owen; M Moore; R Padbury; R Doi; D Smith; MW Buechler

doi:10.1038/sj.bjc.6604838

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials

JP Neoptolemos, Deborah Stocken, CT Smith, C Bassi, P Ghaneh, E Owen, M Moore, R Padbury, R Doi, D Smith, MW Buechler

Research output: Contribution to journal › Article

150 Citations (Scopus)

Abstract

The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.

Original language	English
Pages (from-to)	246-250
Number of pages	5
Journal	British Journal of Cancer
Volume	100
Issue number	2
DOIs	https://doi.org/10.1038/sj.bjc.6604838
Publication status	Published - 1 Jan 2009

Keywords

pancreatic cancer
randomized trial
gemcitabine
chemoradiation
5-flurouracil

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6604838

Cite this

@article{17ec20425de046a9a9b2b94fd730c184,

title = "Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials",

abstract = "The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.",

keywords = "pancreatic cancer, randomized trial, gemcitabine, chemoradiation, 5-flurouracil",

author = "JP Neoptolemos and Deborah Stocken and CT Smith and C Bassi and P Ghaneh and E Owen and M Moore and R Padbury and R Doi and D Smith and MW Buechler",

year = "2009",

month = jan,

day = "1",

doi = "10.1038/sj.bjc.6604838",

language = "English",

volume = "100",

pages = "246--250",

journal = "British Journal of Cancer",

publisher = "Cancer Research UK",

number = "2",

}

TY - JOUR

T1 - Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials

AU - Neoptolemos, JP

AU - Stocken, Deborah

AU - Smith, CT

AU - Bassi, C

AU - Ghaneh, P

AU - Owen, E

AU - Moore, M

AU - Padbury, R

AU - Doi, R

AU - Smith, D

AU - Buechler, MW

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.

AB - The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.

KW - pancreatic cancer

KW - randomized trial

KW - gemcitabine

KW - chemoradiation

KW - 5-flurouracil

U2 - 10.1038/sj.bjc.6604838

DO - 10.1038/sj.bjc.6604838

M3 - Article

C2 - 19127260

VL - 100

SP - 246

EP - 250

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 2

ER -

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this